viewScancell Holdings PLC

Scancell hails first antibody collaboration deal

The company is teaming up with an unnamed "major player" in the world of antibodies

Scancell Holdings PLC -
Scancell’s breakthrough is called AvidiMab, which works with monoclonal antibodies

Scancell Holdings PLC (LON:SCLP) has signed its first collaboration deal with an unnamed “leading antibody technology company” as it bids to develop an early-stage technology created to directly kill tumour cells.

Under the terms of the agreement, the two will assess the technology in various formats including antibody-drug conjugates, where the antibody is linked to a drug; as bispecific antibodies that combine two or more cancer toxins; and as stand-alone antibody products.

WATCH: Antibody collaboration deal for Scancell

Scancell’s breakthrough is called AvidiMab, which works with monoclonal antibodies that already form the basis of some very effective targeted cancer treatments.

The mAbs being developed by the AIM-listed drug developer are different, however, to the run of the mill antibody.

That’s because they target tumour-associated glycans that are associated with malignancies. The ability to hone in on these so-called TaGs is enhanced with the use of AvidiMab.

Scancell has produced a pipeline of these next-generation antibodies for use in the collaboration process.

“Our first collaboration and evaluation agreement with one of the major players in the antibody development field is a significant achievement in such a short period of time and we believe our novel AvidiMab enhanced cell killing platform has broad partnering potential," said chief executive, Dr Cliff Holloway.

Quick facts: Scancell Holdings PLC

Price: 23 GBX

Market: LSE
Market Cap: £187.5 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Scancell Holdings PLC named herein, including the promotion by the Company of Scancell Holdings PLC in any Content on the Site, the Company...


Scancell Holdings highlights 'most transformative period Scancell has ever...

Scancell Holdings PLC's (LON:SCLP) Cliff Holloway talks to Proactive London about the six month period ending ended October 31, 2020, described by Holloway as the 'most transformative period Scancell has ever experienced'. He highlights their strengthened cash position, 'which has allowed us...

3 weeks, 5 days ago

2 min read